Silver Spring, Maryland—(ENEWSPF)—November 16, 2017
By: Angela Stark
The U.S. Food and Drug Administration (FDA) today approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy). Adjuvant treatment is a form of therapy that is taken after an initial surgical removal to lower the risk of the cancer…
